We address the underlying causes of ophthalmic diseases
Okogen is an ophthalmic specialty pharmaceutical company focused on developing the leading treatment for both bacterial and viral conjunctivitis.
Our lead product candidate, OKG-0303, is being developed to treat infectious conjunctivitis. It is a fixed dose eyedrop consisting of a proprietary antiviral, an ocular decongestant and an antibacterial agent.
There are 6 million new cases of acute conjunctivitis per year in United States.